ArticleBMC medicine2025
Burden of bacterial antimicrobial resistance 1990-2021 in China: a systematic analysis for the global burden of disease study 2021.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Can we escape from top-priority ESKAPE pathogens?Emerging microbes & infections · 2026Review
- Growth-Inhibitory Activity of Raw and Pasteurized Donkey Milk Against Clinically Relevant Gram-Negative Isolates with Different Antimicrobial Resistance Profiles.Animals : an open access journal from MDPI · 2026Article
- Transforming long-term post-acute care for the aging population through home infusion therapy in China: an assessment of need and demand (Part 1).Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundChina is confronted with a severe burden of antimicrobial resistance (AMR), and to date, there has been no comprehensive estimate of the historical trend of the AMR burden in China.
methodsData on AMR were collected by the Global Antimicrobial Resistance Burden study 1990-2021. Logistic regression, polynomial models, stacked ensemble models, spatiotemporal Gaussian regression models, and mixed-effects meta-regression models are incorporated into the modeling framework to fit the burden of AMR and estimate the number of deaths and disability-adjusted life-years (DALYs) attributable to and associated with AMR in two counterfactual scenarios.
resultsIn 2021, it was estimated that 711,852 (95% uncertainty interval [UI] (586,447-837,256) deaths were associated with bacterial AMR in China, including 160,268 (132,375-188,160) deaths attributable to bacterial AMR. From 1990 to 2021, the number of deaths attributable to AMR among children under 5 years old declined by 95%, while that among the elderly aged 65 and above increased by 68%. Among the 12 infectious syndromes, the top three with the largest number of deaths attributed to AMR in 2021 were bloodstream infections (74,119), lower respiratory tract infections (60,839), and peritoneal and intra-abdominal infections (11,827). Among them, bloodstream infections were the infectious syndrome with the greatest increase in the number of deaths during the study period. In 2021, the pathogen with the highest number of deaths attributed to AMR was Staphylococcus aureus (39,643), and the one with the greatest increase in attributed deaths was Staphylococcus aureus, with an increase of 20,774 (16,880-24,668). In 2021, the pathogen-drug combination causing the highest number of AMR-attributed deaths was methicillin-resistant Staphylococcus aureus (26,023), and the pathogen with the highest annualized rate of change in attributed deaths over 31 years was third-generation cephalosporin-resistant Acinetobacter baumannii (17.5%).
conclusionsBacterial antimicrobial resistance in China was a serious threat to public health, especially for elderly people. Meanwhile, intervention measures such as popularizing vaccination, reducing the misuse of antibiotics, and developing new antibiotics should be combined to address this significant health threat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.